The frequency and profile of drug treatment in subjects with dyslipidemias and cardimetabolic diseases in an urban russian population older then 55 years

Malyutina, Sofia; Маздорова, Е. В.; Shapkina, Marina; Avdeeva, E. Yu.; Simonova, Galina; Hubacek, Jaroslav A.; Bobák, Martin; Nikitin, Yu. P.; Ryabikov, Andrey

doi:10.18087/cardio.2021.12.n1558

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early findings on drug therapy for atrial fibrillation, antihypertensive and lipid-lowering therapy in the studied population have previously been reported [ 20 , 21 , 22 ]. The present paper continues a systematic series of works on the pharmacotherapy of cardiometabolic diseases in the modern Russian population, using a population-based urban sample of older age persons in Novosibirsk.…”

Section: Introductionmentioning

confidence: 99%

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

Malyutina

Mazurenko

Маздорова

et al. 2022

JPM

View full text Add to dashboard Cite

We aimed to analyze the profile of glucose lowering therapy (GLT) in persons with diabetes mellitus type 2 (DM2) in an aging Russian population. A random population sample (n = 3898, men/women, 55–84) was examined in Novosibirsk, during 2015–2018 (HAPIEE Project). The design of the present work is a cross-sectional study. DM2 was defined in those with a history of DM2 receiving GLT, or at a level of fasting plasma glucose (FPG) ≥7.0 mmol/L. The entire DM2 group was included in the analysis (n = 803); of these, 476 persons were taking GLT and were included in the analysis at stage 2. Regular GLT medication intake for 12 months was coded with ATC. In studied sample, the prevalence of DM2 was 20.8%. Among subjects with DM2, 59% of individuals received GLT, 32% did not. Glycemic control (FPG < 7.0 mmol/L) was achieved in every fifth participant with DM2 (35% in those receiving GLT). In frequency of GLT use, biguanides ranked in first place (75%), sulfonylurea derivatives in second (35%), insulins in third (12%), and iDPP-4 in fourth (5%). Among those receiving GLT, 24% used combined oral therapy, and 6% used insulin-combined therapy. In conclusion, in a population sample aged 55–84 examined in 2015–2018, glycemic control was achieved in every fifth participant with DM2, and in every third participant receiving GLT. The proportion of participants using new GLT drugs was small, and there was a lack of HbA1c monitoring for intensive glycemic control.

show abstract

Section: Introductionmentioning

confidence: 99%

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

Malyutina

Mazurenko

Маздорова

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…Te HAPIEE study (2002)(2003)(2004)(2005) showed relatively low awareness of diabetes (30.8% in males and 45.2% in females) and hypercholesterolemia (11.2% in males and 15.3% in females) in Russia compared with Poland, Lithuania, and the Czech Republic [3]. Several studies assessed the control of DM and high cholesterol [25][26][27], but we could not fnd Russian population-based studies focusing behavioral and health characteristics associated with the awareness.…”

Section: Introductionmentioning

confidence: 99%

Awareness of Hypertension, Hypercholesterolemia, and Diabetes Mellitus and Associated Characteristics in Russian Adults

Sahatqija,

Hunsberger,

Cook

et al. 2024

International Journal of Hypertension

Self Cite

View full text Add to dashboard Cite

Russia has higher cardiovascular disease (CVD) mortality compared to other European countries. The major CVD risk factors are age, male sex, and three conditions, namely hypertension, hypercholesterolemia, and diabetes mellitus (DM). This study aimed to assess awareness of these three conditions among Russian adults (N = 3803) and the associated socio-demographic, lifestyle, and health characteristics. We used cross-sectional data from a randomly drawn population-based sample of Russians aged 35–69 years, who participated in the Know Your Heart (KYH) study conducted in Arkhangelsk and Novosibirsk between 2015–2018. Participants’ self-reported awareness of hypertension, hypercholesterolemia, and DM was assessed against the measures at the KYH health check (blood pressure, cholesterol, HbA1c and/or use of medication for each condition). Prevalence estimates for the awareness were age- and sex-standardized to the Standard European Population. Socio-demographic, lifestyle, and health-related correlates of the awareness were investigated using logistic regression modelling. Among participants with hypertension (N = 2206), hypercholesterolemia (N = 3171), and DM (N = 329) recorded at a health check, 79%, 45%, and 61% self-reported these conditions, respectively. Higher awareness of hypercholesterolemia and hypertension was associated with older age, female sex, nonsmoking status, obesity, and history of CVD diagnoses. Low household income and history of CVD diagnoses were associated with being aware of DM. The awareness rates of hypertension were relatively high, whereas awareness rates of hypercholesterolemia and DM were relatively low. CVD prevention and early intervention could be improved in Russia through increasing the awareness of the risk factors.

show abstract

Association of non-high-density lipoprotein hypercholesterol with metabolic syndrome, diabetes and arterial hypertension in the population of 45–69 years adults

et al. 2022

View full text Add to dashboard Cite

Objective. To study the prevalence of non-high-density lipoprotein hypercholesterol (non-HDL–C) and the average levels of non-HDL–C in metabolic syndrome (MS), type 2 diabetes mellitus (DM2), arterial hypertension (AH) and other cardiometabolic risk factors in the Siberian population aged 45–69 years.Design and methods. The evaluation of atherogenic dyslipidemia among persons with AН, MS, T2D was based on the materials of Siberian branch of HAPIEE project in the random sample n = 9360 surveyed in 2003–2005 HAPIEE. The study program included questionnaire survey, blood pressure (BP) measurement, anthropometry, biochemical screening. The value ≥ 3,4 mmol/l was considered as hypercholesterol-non-HDL. AH was diagnosed at systolic BP levels ≥ 140 mm hg. art. or diastolic BP ≥ 90 mm hg. art. and/or taking antihypertensive drugs within the last 2 weeks. Persons with previously diagnosed AH, but with normotonia at screening in cases of taking drugs that reduce BP, were also counted as patients with AH. DM2 was diagnozed — according to WHO criteria, 1999, ADA, 2013 — at fasted plasma glucose level ≥ 7,0 mmol/l and persons with previously diagnosed DM2. MS and its components were diagnosed according to IDF criteria (2005).Results. The mean value of non-HDL cholesterol in the general population of Novosibirsk aged 45–69 were 4,7 ± 1,3 mmol/l and were higher in women than in men — 4,9 ± 1,3 mmol/l and 4,5 ± 1,2 mmol/l, (p < 0,0001). The prevalence of hypercholesterol-non-HDL in women varies from 84,7 to 94,3% — and is significantly higher than in men — 80,6 to 84,1%. The level of non-HDL cholesterol ≥ 3,4 mmol/l was observed in 86,8% of the examined, 11% — in the range of 2,6–3,39 and only 2,2% — less than 2,6 mmol/l. The average values of non-HDL–C in men and women in three cohorts (with DM2, MS and AH) were found to be the highest in DM2, lower in MS than in DM, and lower in AH than in MS and DM2. In the cohort with DM2, non-HDL–C, according to the criterion of non-HDL–C ≥ 3,4 mmol/l, was determined in 89,4% of men and 95,7% of women; in persons with MS, it was found in 92,4% of men and 95,1% of women, with AH — in 85,2% of men and 92,5% of women of the Siberian population aged 45–69 years. The frequencies of AH, MS and DM2 in the 5th quintile of the distribution of non-HDL–C are higher compared to the first quintile (p < 0,0001), with a predominance of these indicators in the female population.Conclusions. According to study, the content of non-HDL–C, and its prevalence of elevated levels in the population is high, especially in people with DM2, MS, AH. In terms of developing a platform for prevention of cardiovascular diseases, MS and DM2, the non-HDL–C ratio deserves attention as a target for further research.

show abstract

The frequency and profile of drug treatment in subjects with dyslipidemias and cardimetabolic diseases in an urban russian population older then 55 years

Cited by 3 publications

References 32 publications

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

Awareness of Hypertension, Hypercholesterolemia, and Diabetes Mellitus and Associated Characteristics in Russian Adults

Association of non-high-density lipoprotein hypercholesterol with metabolic syndrome, diabetes and arterial hypertension in the population of 45–69 years adults

Contact Info

Product

Resources

About